Intravenous zoledronate for postmenopausal osteoporosis
To determine the efficacy and safety of zoledronic acid therapy in the prevention and treatment of postmenopausal osteoporosis compared to placebo or active comparator (other bisphosphonates).
We are collecting information on visitors to our website to ensure Cochrane resources meet the needs of our users. Your data will be anonymised for processing, will be stored securely, and will not be shared with any third parties.